Fibulin-3 Suppresses Wnt/β-catenin Signaling and Lung Cancer Invasion
Overview
Affiliations
The 5 year survival rate of lung cancer is <20%, with most patients dying from distant metastasis. However, the molecular mechanisms underlying lung cancer invasion and metastasis have not been fully characterized. In this study, we found that fibulin-3, a fibulin family extracellular matrix protein, functions as a suppressor of lung cancer invasion and metastasis. Fibulin-3 was downregulated in large fractions of lung tumors and cell lines, and inhibited lung cancer cell invasion and the expression of matrix metalloproteinase-7 (MMP-7), a promoter of lung cancer invasion. The expression levels of fibulin-3 and MMP-7 were inversely correlated in lung tumors. Fibulin-3 inhibited extracellular signal-regulated kinase (ERK) to activate glycogen synthase kinase 3β and suppress Wnt/β-catenin signaling, which induces MMP-7 expression in lung cancer cells. Furthermore, fibulin-3 expression impeded the growth and metastasis of lung tumors in mice. Collectively, these results suggest that downregulation of fibulin-3 contributes to lung cancer invasion and metastasis by activating Wnt/β-catenin signaling and MMP-7 expression.
Wnt/β-catenin signaling in the development and therapeutic resistance of non-small cell lung cancer.
Zhang Z, Westover D, Tang Z, Liu Y, Sun J, Sun Y J Transl Med. 2024; 22(1):565.
PMID: 38872189 PMC: 11170811. DOI: 10.1186/s12967-024-05380-8.
The multifaceted roles of matrix metalloproteinases in lung cancer.
Wei C Front Oncol. 2023; 13:1195426.
PMID: 37766868 PMC: 10520958. DOI: 10.3389/fonc.2023.1195426.
Function and prognostic value of basement membrane -related genes in lung adenocarcinoma.
Zhang Y, Li T, Liu H, Wang L Front Pharmacol. 2023; 14:1185380.
PMID: 37214471 PMC: 10196008. DOI: 10.3389/fphar.2023.1185380.
Sharma P, Beck D, Murtha L, Figtree G, Boyle A, Gentile C Front Cardiovasc Med. 2022; 9:913156.
PMID: 35795376 PMC: 9251181. DOI: 10.3389/fcvm.2022.913156.
Hassanein S, Abdel-Mawgood A, Ibrahim S Front Oncol. 2022; 11:766659.
PMID: 34976811 PMC: 8714827. DOI: 10.3389/fonc.2021.766659.